Effects of Music Therapy Assisted Anagliptin on Glycolipid Metabolism in Patients with Type 2 Diabetes

doi:10.12114/j.issn.1007-9572.2022.0271

Chinese General Practice ›› 2022, Vol. 25 ›› Issue (26): 3275-3280.DOI: 10.12114/j.issn.1007-9572.2022.0271

• Original Research • Previous Articles Next Articles

Effects of Music Therapy Assisted Anagliptin on Glycolipid Metabolism in Patients with Type 2 Diabetes

1. School of Rehabilitation Medicine, Capital Medical University, Beijing 100068, China
2. Department of Endocrine, Beijing Boai Hospital, China Rehabilitation Research Center, Beijing 100068, China
3. Music Therapy Center, Beijing Boai Hospital, China Rehabilitation Research Center, Beijing 100068, China
4. Department of Neurological Rehabilitation, Beijing Boai Hospital, China Rehabilitation Research Center, Beijing 100068, China

Received:2022-01-27 Revised:2022-05-25 Published:2022-09-15 Online:2022-07-06
Contact: Xin ZHENG
About author:
LI M X, ZHENG X, ZHANG X Y, et al. Effects of music therapy assisted anagliptin on glycolipid metabolism in patients with type 2 diabetes[J]. Chinese General Practice, 2022, 25 (26) : 3275-3280.

音乐辅助阿格列汀对2型糖尿病患者糖脂代谢的影响研究

1．100068　北京市，首都医科大学康复医学院
2．100068　北京市，中国康复研究中心北京博爱医院内分泌科
3．100068　北京市，中国康复研究中心北京博爱医院音乐治疗中心
4．100068　北京市，中国康复研究中心北京博爱医院神经康复科

通讯作者: 郑欣
作者简介:
作者贡献：李梅欣、郑欣负责文章的构思与设计、实施、记录、结果的分析与解释、撰写；张晓颖负责对音乐治疗内容的选择、指导；杜晓霞负责项目的申请及资金支持；郑欣负责文章的质量控制及审校，对文章整体负责。李梅欣，郑欣，张晓颖，等.音乐辅助阿格列汀对2型糖尿病患者糖脂代谢的影响研究[J].中国全科医学，2022，25（26）：3275-3280.[www.chinagp.net]
基金资助:
中国康复研究中心科研项目(2019zx-01)

Abstract

Abstract:

Background

Music therapy, as an emerging treatment, has a gradually evolving role in the rehabilitation of chronic diseases and is gaining increasing attention. But there are few studies on the effects of music therapy on diabetes rehabilitation.

Objective

To observe the effects of music assisted anagliptin on glycolipid metabolism in patients with type 2 diabetes.

Methods

Sixty five type 2 diabetic patients with poor glycemic control on oral agents who visited the outpatient clinic of Department of Endocrinology, Boai Hospital, China Rehabilitation Research Center, from October 2019 to February 2021 were selected. Patients were divided into group A (n=35) and group B (n=30) by random numbers, and patients in both groups maintained their original diet and exercise habits. Group A was treated with anagliptin tablets in combination with the original treatment (drug type, dose unchanged) , while group B was given music adjuvant therapy on the basis of group A. Patients in both groups were treated continuously for 12 weeks. Fasting plasma glucose (FPG) , glycated hemoglobin (HbA_1c) , low-density lipoprotein cholesterol (LDL-C) , total cholesterol (TC) , triacylglycerol (TG) , high-density lipoprotein cholesterol (HDL-C) , uric acid (UA) , 2 h postprandial plasma glucose (2 hPG) , hypersensitivity C-reactive protein (hs-CRP) , free fatty acids (FFA) , insulin resistance index (HOMA-IR) , β Cell function secretion index (HOMA-β) before and 12 weeks after treatment were compared between the two groups. The patients were observed for the occurrence of adverse reactions during the treatment.

Results

One patient was eliminated from the trial because of adverse drug reactions during the course of the trial in both groups, and 34 and 29 patients finally completed the trial in groups A and B, respectively. Patients in group B had lower 2 hPG than those in group A after 12 weeks of treatment (P<0.05) . FPG, HbA_1c, and 2 hPG were lower in both groups after 12 weeks of treatment whereas HOMA-β were higher after treatment (P<0.05) ; LDL-C and TC of group B patients after 12 weeks of treatment were lower (P<0.05) . No hypoglycemic events occurred in either group.

Conclusion

Music-assisted alagliptin can reduce postprandial blood glucose and improve lipid profile of type 2 diabetes patients more than that without music-assisted alagliptin. It also needs to be emphasized that the effects of music therapy must be based on diet control, proper exercise, and rational medication.

Key words: Diabetes mellitus, type 2, Hypoglycemic agents, Anagliptin, Music therapy, Dyslipidemias, Glycemic control, Treatment outcome

摘要：

背景

音乐治疗作为新兴的治疗方法，在慢性疾病康复中的应用逐渐兴起，且日益得到重视。但音乐治疗对糖尿病康复的效果研究尚少见报道。

目的

观察音乐辅助阿格列汀对2型糖尿病患者糖脂代谢的影响。

方法

选取2019年10月至2021年2月在中国康复研究中心北京博爱医院内分泌科门诊就诊的口服药物血糖控制不佳的2型糖尿病患者65例。采用随机数字表法将患者分为A组（n=35）和B组（n=30），两组患者均保持原有饮食、运动习惯。A组在原治疗（药物种类、剂量不变）基础上联用阿格列汀片治疗，B组在A组基础上给予音乐辅助治疗。两组患者均连续治疗12周。比较治疗前及治疗12周后两组患者空腹血糖（FPG）、糖化血红蛋白（HbA_1c）、低密度脂蛋白胆固醇（LDL-C）、总胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白胆固醇（HDL-C）、尿酸（UA）、餐后2 h血糖（2 hPG）、超敏C反应蛋白（hs-CRP）、游离脂肪酸（FFA）、胰岛素抵抗指数（HOMA-IR）、β细胞功能分泌指数（HOMA-β）；观察患者治疗过程中不良反应发生情况。

结果

两组试验过程中因药物不良反应均剔除1例患者，A组、B组最终分别有34、29例患者完成试验。B组患者治疗12周后2 hPG低于A组（P<0.05）。治疗12周后两组患者FPG、HbA_1c、2 hPG均低于组内治疗前，HOMA-β高于组内治疗前（P<0.05）；治疗12周后B组患者LDL-C、TC均低于组内治疗前（P<0.05）。两组均未发生低血糖事件。

结论

音乐辅助阿格列汀较无音乐辅助更能降低2型糖尿病患者的餐后血糖，改善血脂情况。需要强调的是，音乐治疗的效果一定是在饮食控制、适当运动、合理用药的基础上。

关键词: 糖尿病，2型, 降血糖药, 阿格列汀, 音乐治疗, 血脂异常, 血糖控制, 治疗结果

Meixin LI,Xin ZHENG,Xiaoying ZHANG, et al. Effects of Music Therapy Assisted Anagliptin on Glycolipid Metabolism in Patients with Type 2 Diabetes[J]. Chinese General Practice, 2022, 25(26): 3275-3280. DOI: 10.12114/j.issn.1007-9572.2022.0271.
李梅欣,郑欣,张晓颖等. 音乐辅助阿格列汀对2型糖尿病患者糖脂代谢的影响研究[J]. 中国全科医学, 2022, 25(26): 3275-3280. DOI: 10.12114/j.issn.1007-9572.2022.0271.

Figures/Tables 2

References 24

[1]	潘长玉，陆菊明，李文慧，等. 阿格列汀治疗2型糖尿病的有效性与安全性中国大陆多中心、随机、双盲、安慰剂对照Ⅲ期临床研究[J]. 中华内科杂志，2015，54(11):949-953. DOI：10.3760/cma.j.issn.0578-1426.2015.11.010.
[2]	KITAO N, MIYOSHI H, FURUMOTO T，et al. The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters：a randomized，controlled trial （Sapporo Athero-Incretin Study 3）[J]. Cardiovasc Diabetol，2017，16(1):125. DOI：10.1186/s12933-017-0607-6.
[3]	张鸿懿. 音乐治疗学基础[M]. 北京：中国电子音像出版社，2000：131-139.
[4]	DO AMARAL M A, NETO M G, DE QUEIROZ J G，et al. Effect of music therapy on blood pressure of individuals with hypertension：a systematic review and Meta-analysis[J]. Int J Cardiol，2016，214:461-464. DOI：10.1016/j.ijcard.2016.03.197.
[5]	KÜHLMANN A Y R, ETNEL J R G, ROOS-HESSELINK J W，et al. Systematic review and meta-analysis of music interventions in hypertension treatment：a quest for answers[J]. BMC Cardiovasc Disord，2016，16:69. DOI：10.1186/s12872-016-0244-0.
[6]	VLACHOPOULOS C, AGGELAKAS A, IOAKEIMIDIS N，et al. Music decreases aortic stiffness and wave reflections[J]. Atherosclerosis，2015，240(1):184-189. DOI：10.1016/j.atherosclerosis.2015.03.010.
[7]	VANDERLEI F M, DE ABREU L C, GARNER D M，et al. Symbolic analysis of heart rate variability during exposure to musical auditory stimulation[J]. Altern Ther Health Med，2016，22(2):24-31.
[8]	ROQUE A L, VALENTI V E, GUIDA H L，et al. The effects of auditory stimulation with music on heart rate variability in healthy women[J]. Clinics （Sao Paulo），2013，68(7):960-967. DOI：10.6061/clinics/2013(07)12.
[9]	MARTINIANO E C, SANTANA M D R, BARROS É L D，et al. Musical auditory stimulus acutely influences heart rate dynamic responses to medication in subjects with well-controlled hypertension[J]. Sci Rep，2018，8(1):958. DOI：10.1038/s41598-018-19418-7.
[10]	NILSSON U. Soothing music can increase oxytocin levels during bed rest after open-heart surgery：a randomised control trial[J]. J Clin Nurs，2009，18(15):2153-2161. DOI：10.1111/j.1365-2702.2008.02718.x.
[11]	World Health Organization. Definition，diagnosis and classification of diabetes mellitus and its complications：report of a WHO consultation. Part 1，Diagnosis and classification of diabetes mellitus[R/OL].[2021-08-10]. Geneva：World Health Organization，1999.
[12]	中华医学会糖尿病学分会胰岛素抵抗学组（筹）. 胰岛素抵抗评估方法和应用的专家指导意见[J]. 中华糖尿病杂志，2018，10(6):377-385. DOI：10.3760/cma.j.issn.1674-5809.2018.06.001.
[13]	KAY S, STRICKSON A, PUELLES J，et al. Comparative effectiveness of adding alogliptin to metformin plus sulfonylurea with other DPP-4 inhibitors in type 2 diabetes：a systematic review and network meta-analysis[J]. Diabetes Ther，2017，8(2):251-273. DOI：10.1007/s13300-017-0245-8.
[14]	MASUY I, ROTONDO A, VERBEURE W，et al. Editorial：effects of vildagliptin on GLP-1 levels，gastric motor functions and food intake. A authors' reply[J]. Aliment Pharmacol Ther，2019，49(10):1363-1364. DOI：10.1111/apt.15242.
[15]	TOMASOVA P, BUGÁNOVÁ M, PELANTOVÁ H，et al. Metabolomics based on MS in mice with diet-induced obesity and type 2 diabetes mellitus：the effect of vildagliptin，metformin，and their combination[J]. Appl Biochem Biotechnol，2019，188(1):165-184. DOI：10.1007/s12010-018-2899-8.
[16]	PEVELER J L, HICKMAN D L. Effects of music enrichment on individually housed male New Zealand white rabbits[J]. J Am Assoc Lab Anim Sci，2018，57(6):695-697. DOI：10.30802/AALAS-JAALAS-17-000153.
[17]	RAGLIO A, GALANDRA C, SIBILLA L，et al. Effects of active music therapy on the normal brain：fMRI based evidence[J]. Brain Imaging Behav，2016，10(1):182-186. DOI：10.1007/s11682-015-9380-x.
[18]	SALIMPOOR V N, BENOVOY M, LARCHER K，et al. Anatomically distinct dopamine release during anticipation and experience of peak emotion to music[J]. Nat Neurosci，2011，14(2):257-262. DOI：10.1038/nn.2726.
[19]	VALENTI V E, GUIDA H L, FRIZZO A C F，et al. Auditory stimulation and cardiac autonomic regulation[J]. Clinics （Sao Paulo），2012，67(8):955-958. DOI：10.6061/clinics/2012(08)16.
[20]	NAKAMURA T, TANIDA M, NIIJIMA A，et al. Effect of auditory stimulation on parasympathetic nerve activity in urethane-anesthetized rats[J]. In Vivo，2009，23(3):415-419.
[21]	SANTANA M D R, MARTINIANO E C, MONTEIRO L R L，et al. Musical auditory stimulation influences heart rate autonomic responses to endodontic treatment[J]. Evid Based Complement Alternat Med，2017，2017:4847869. DOI：10.1155/2017/4847869.
[22]	WILLIAMS R, KOTHNY W, SERBAN C，et al. Pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus：a European，noninterventional，postauthorization safety study[J]. Endocrinol Diabetes Metab，2019，2(2):e00052. DOI：10.1002/edm2.52.
[23]	STRAIN W D, MCEWAN P, HOWITT H，et al. Retrospective database analysis evaluating the clinical outcomes of changing treatment of people with type 2 diabetes mellitus （T2DM） from other DPP-4 inhibitor therapy to alogliptin in a primary care setting[J]. Diabetes Ther，2019，10(4):1499-1507. DOI：10.1007/s13300-019-0662-y.
[24]	LING J, CHENG P, GE L，et al. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes：a Bayesian network meta-analysis of 58 randomized controlled trials[J]. Acta Diabetol，2019，56(3):249-272. DOI：10.1007/s00592-018-1222-z.

组别	例数	年龄（岁）	性别（男/女）	病程（年）	BMI（kg/m²）	eGFR〔ml·min^-1·（1.73 m²）^-1〕	SBP（mm Hg）	DBP（mm Hg）
A组	34	58.3±12.1	20/14	8.9±2.0	24.8±3.6	94.47±19.28	134±15	78±11
B组	29	56.7±12.6	16/13	9.1±2.2	25.1±3.6	95.35±20.12	135±15	79±11
t（χ²）值		0.341	0.059^a	-0.781	0.331	0.551	-0.296	0.314
P值		0.736	0.803	0.435	0.750	0.597	0.769	0.755

组别	例数	年龄（岁）	性别（男/女）	病程（年）	BMI（kg/m²）	eGFR〔ml·min^-1·（1.73 m²）^-1〕	SBP（mm Hg）	DBP（mm Hg）
A组	34	58.3±12.1	20/14	8.9±2.0	24.8±3.6	94.47±19.28	134±15	78±11
B组	29	56.7±12.6	16/13	9.1±2.2	25.1±3.6	95.35±20.12	135±15	79±11
t（χ²）值		0.341	0.059^a	-0.781	0.331	0.551	-0.296	0.314
P值		0.736	0.803	0.435	0.750	0.597	0.769	0.755

组别	例数	FPG（mmol/L）				HbA_1c（%）				LDL-C（mmol/L）
组别	例数	治疗前	治疗12周后	t_配对值	P值	治疗前	治疗12周后	t_配对值	P值	治疗前	治疗12周后	t_配对值	P值
A组	34	8.20±1.19	7.29±1.17	2.295	0.031	7.92±0.75	7.22±0.61	2.941	0.008	2.48±0.77	2.40±0.71	0.151	0.201
B组	29	8.39±1.03	7.07±0.98	4.041	0.001	8.18±1.03	7.20±0.90	3.296	0.004	2.92±0.72	2.60±0.79	0.201	0.034
t（Z）值		1.163	-0.955			0.822	0.098			1.730	0.969
P值		0.252	0.346			0.416	0.922			0.092	0.339
组别	TC（mmol/L）				TG（mmol/L）				HDL-C（mmol/L）
组别	治疗前	治疗12周后	t_配对值	P值	治疗前	治疗12周后	t_配对值	P值	治疗前	治疗12周后	t_配对值	P值
A组	4.67±1.05	4.38±0.96	-1.749	0.096	1.78±1.02	1.55±0.97	0.644	0.527	1.16±0.32	1.18±0.21	-0.129	0.899
B组	4.83±0.92	4.36±0.98	0.255	0.001	1.85±1.16	1.60±0.85	0.787	0.441	1.17±0.21	1.24±0.24	-0.923	0.368
t（Z）值	0.482	0.319			0.325	0.182			0.355	0.957
P值	0.632	0.751			0.747	0.857			0.724	0.345
组别	UA（μmol/L）				2 hPG（mmol/L）				hs-CRP〔M（QR），mg/d〕
组别	治疗前	治疗12周后	t_配对值	P值	治疗前	治疗12周后	t_配对值	P值	治疗前	治疗12周后	Z值	P值
A组	360.92±29.11	327.00±21.85	1.661	0.123	11.60±1.70	9.72±1.65	3.979	0.001	0.12（0.27）	0.11（0.17）	0.541	0.594
B组	339.77±34.16	304.85±41.75	1.505	0.171	11.42±1.47	8.76±1.10	14.130	<0.001	0.11（0.18）	0.11（0.21）	0.458	0.654
t（Z）值	-1.632	-1.099			-0.199	-2.163			-0.038^a	-0.032^a
P值	0.114	0.281			0.844	0.037			0.970	0.742
组别	FFA（mmol/L）				HOMA-IR				HOMA-β
组别	治疗前	治疗12周后	t_配对值	P值	治疗前	治疗12周后	t_配对值	P值	治疗前	治疗12周后	t_配对值	P值
A组	0.50±0.20	0.52±0.23	-0.283	0.780	3.96±2.48	3.70±1.68	1.322	0.202	52.26±23.26	79.03±27.26	-3.256	0.005
B组	0.44±0.21	0.57±0.28	-1.534	0.141	4.26±2.65	4.08±2.14	0.746	0.467	53.93±29.07	86.88±54.95	-3.432	0.005
t（Z）值	-0.317	0.656			0.478	0.320			1.218	0.909
P值	0.753	0.516			0.645	0.753			0.234	0.380

组别	例数	FPG（mmol/L）				HbA_1c（%）				LDL-C（mmol/L）
组别	例数	治疗前	治疗12周后	t_配对值	P值	治疗前	治疗12周后	t_配对值	P值	治疗前	治疗12周后	t_配对值	P值
A组	34	8.20±1.19	7.29±1.17	2.295	0.031	7.92±0.75	7.22±0.61	2.941	0.008	2.48±0.77	2.40±0.71	0.151	0.201
B组	29	8.39±1.03	7.07±0.98	4.041	0.001	8.18±1.03	7.20±0.90	3.296	0.004	2.92±0.72	2.60±0.79	0.201	0.034
t（Z）值		1.163	-0.955			0.822	0.098			1.730	0.969
P值		0.252	0.346			0.416	0.922			0.092	0.339
组别	TC（mmol/L）				TG（mmol/L）				HDL-C（mmol/L）
组别	治疗前	治疗12周后	t_配对值	P值	治疗前	治疗12周后	t_配对值	P值	治疗前	治疗12周后	t_配对值	P值
A组	4.67±1.05	4.38±0.96	-1.749	0.096	1.78±1.02	1.55±0.97	0.644	0.527	1.16±0.32	1.18±0.21	-0.129	0.899
B组	4.83±0.92	4.36±0.98	0.255	0.001	1.85±1.16	1.60±0.85	0.787	0.441	1.17±0.21	1.24±0.24	-0.923	0.368
t（Z）值	0.482	0.319			0.325	0.182			0.355	0.957
P值	0.632	0.751			0.747	0.857			0.724	0.345
组别	UA（μmol/L）				2 hPG（mmol/L）				hs-CRP〔M（QR），mg/d〕
组别	治疗前	治疗12周后	t_配对值	P值	治疗前	治疗12周后	t_配对值	P值	治疗前	治疗12周后	Z值	P值
A组	360.92±29.11	327.00±21.85	1.661	0.123	11.60±1.70	9.72±1.65	3.979	0.001	0.12（0.27）	0.11（0.17）	0.541	0.594
B组	339.77±34.16	304.85±41.75	1.505	0.171	11.42±1.47	8.76±1.10	14.130	<0.001	0.11（0.18）	0.11（0.21）	0.458	0.654
t（Z）值	-1.632	-1.099			-0.199	-2.163			-0.038^a	-0.032^a
P值	0.114	0.281			0.844	0.037			0.970	0.742
组别	FFA（mmol/L）				HOMA-IR				HOMA-β
组别	治疗前	治疗12周后	t_配对值	P值	治疗前	治疗12周后	t_配对值	P值	治疗前	治疗12周后	t_配对值	P值
A组	0.50±0.20	0.52±0.23	-0.283	0.780	3.96±2.48	3.70±1.68	1.322	0.202	52.26±23.26	79.03±27.26	-3.256	0.005
B组	0.44±0.21	0.57±0.28	-1.534	0.141	4.26±2.65	4.08±2.14	0.746	0.467	53.93±29.07	86.88±54.95	-3.432	0.005
t（Z）值	-0.317	0.656			0.478	0.320			1.218	0.909
P值	0.753	0.516			0.645	0.753			0.234	0.380

Effects of Music Therapy Assisted Anagliptin on Glycolipid Metabolism in Patients with Type 2 Diabetes

音乐辅助阿格列汀对2型糖尿病患者糖脂代谢的影响研究

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 24

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	YAO Yuzhong, MA Xiaojun, SONG Huan, ZHONG Yu. The Management Effect of Diabetes "1358 model" on Community Diabetes Patients Based on "Precision Management Combining General Care and Specialty Care" [J]. Chinese General Practice, 2023, 26(34): 4308-4314.
[2]	LIANG Xiaoxian, YANG Jin, JIN Juzhen, ZHOU Jing, HU Jin, GAI Yun, DING Xiaoyun, WANG Junhua, WANG Ziyun. Association between Chronotype and Dyslipidemia among Population Aged 40-65 Years [J]. Chinese General Practice, 2023, 26(34): 4277-4282.
[3]	YANG Hui, HU Ruwei, LIU Ruqing, LU Junfeng, WU Jinglan. Relationship between Community Health Service Experience and Glycemic Control Outcomes in Patients with Diabetes Mellitus [J]. Chinese General Practice, 2023, 26(34): 4290-4295.
[4]	LI Qian, ZHANG Yunshu, YAN Baoping, WANG Jian, MA Yanjuan, WANG Yuan, QIN Yingjie, NA Long, REN Zhiyong, SUN Junwei, DENG Huaili, MA Hongjun, QU Xuehui, ZHOU Nan, SI Tianmei. Efficacy and Safety of Risperidone Microspheres for Injection (Ⅱ) in the Treatment of Patients with Acute Schizophrenia [J]. Chinese General Practice, 2023, 26(32): 4007-4012.
[5]	HE Yingmei, JIA Xue, ZHU Guojun, LIU Bing. Effect of Serum Uric Acid Longitudinal Trajectory on New-onset Hypertriglyceridemia: a Prospective Cohort Study [J]. Chinese General Practice, 2023, 26(29): 3636-3639.
[6]	CHENG Xiaoran, ZHANG Xiaotian, LI Mingyue, CHENG Haozhe, TANG Haoqing, ZHENG Huixian, ZHANG Baisong, LIU Xiaoyun. Impact of Chronic Diseases Follow-up on Health Behaviors and Blood Pressure/Glucose Control of Patients with Hypertension and Diabetes in the Context of Treatment-prevention Integration [J]. Chinese General Practice, 2023, 26(28): 3482-3488.
[7]	HUANG Qixian, WEN Yanting, HUANG Jun, LI Weibin, XU Yongneng, LIN Xiayi, WANG Haoxiang, WENG Fan, YANG Lianping. Prevalence of Dyslipidemia and Its Influencing Factors among Elderly Community Residents [J]. Chinese General Practice, 2023, 26(28): 3520-3525.
[8]	YAO Junjie, SHANG Qiangqiang, WANG Yufeng, LI Jiahui, LIU Chang, PANG Tingting. Wearable Inertial Sensors-based Efficacy Evaluation of Comprehensive Traditional Chinese Medicine Therapy for Lumbar Disc Herniation Due to Qi-stagnation and Blood-stasis [J]. Chinese General Practice, 2023, 26(27): 3450-3455.
[9]	LIU Minghao, WANG Pan, GAO Lijian, XU Shuqing, WANG Huanhuan, ZHAO Guangxian, CHEN Jue, QIAO Shubin, XU Bo, YUAN Jinqing. Feasibility, Safety and Timing of Secondary Percutaneous Coronary Intervention via Distal Transradial Artery Approach [J]. Chinese General Practice, 2023, 26(27): 3366-3372.
[10]	LU Bin, XIANG Chong, YUAN Xuesong, CAI Gaojun, WEI Wenfeng, YAN Yongmin. Effectiveness, Safety and Satisfaction of Distal Transradial Artery Approach in Cerebral Angiography [J]. Chinese General Practice, 2023, 26(27): 3378-3382.
[11]	BIAN Lili, LI Xiaoxiao, DU Xueping, DAI Qinfang, WU Lin, SONG Beibei. Risk Stratification of Atherosclerotic Cardiovascular Disease and Lipid Goal Attainment in Hypertensive Patients Registered in Community [J]. Chinese General Practice, 2023, 26(27): 3388-3391.
[12]	ZHOU Shiyu, CHEN Shaolin, DENG Renli, DAI Mi, LIU Tao, TIAN Kunming. The Association and Predictive Value of Lipid Ratios to Metabolic Syndrome: a Multistage Cross-sectional Study [J]. Chinese General Practice, 2023, 26(21): 2589-2596.
[13]	GAO Yang, WANG Yunxia, GAO Chuanyu. Familial Hypercholesterolemia in 45-year-old and Younger Patients with Acute Coronary Syndrome: Clinical Characteristics and Influencing Factors of Blood Lipid Control Effect [J]. Chinese General Practice, 2023, 26(18): 2232-2237.
[14]	LIU Li, LI Jing, LIU Xiaofang, HE Jidong. Targets for Individualized Inpatient Management of Hyperglycemia [J]. Chinese General Practice, 2023, 26(15): 1824-1830.
[15]	ZHANG Lina, WANG Yan, ZHANG Kanghuai, LI Youjia. Clinical Research Progress of Tirzepatide: a New Hypoglycemic Agent [J]. Chinese General Practice, 2023, 26(15): 1902-1908.